Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled cisplatin in stage IV NSCLC patients.

With the educational support of:

You may also be interested in:

PULSE, a non-inferiority study of maintenance Pembro at Usual or Low doSE

A network meta-analysis of perioperative IO for resectable NSCLC

Real-world evidence of IO treatment in lung cancer: a Belgian multicenter study

Tags:

poster